Bluejay Diagnostics Inc SEC Filings

Bluejay Diagnostics filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $1,597,632 for the quarter and $5,418,671 for the nine-month period. Operating expenses were $1,616,947 in the quarter, led by research and development of $785,608 and general and administrative of $831,339.

Cash and cash equivalents were $3,082,268 with current liabilities of $1,148,913, and accumulated deficit reached $40,087,455. Management states that these results, combined with expected negative cash flows, raise substantial doubt about the company’s ability to continue as a going concern. A private placement in October 2025 generated ~$4.5 million gross proceeds, and the company estimates its cash resources can fund operations into the third quarter of 2026.

Bluejay continues developing its Symphony IL-6 test for sepsis, advancing the SYMON-II pivotal study with approximately half of the targeted enrollment achieved by quarter-end. The company expects to need to raise at least $20 million through 2027 to complete manufacturing redevelopment, clinical work, and prepare a 510(k) submission targeted for 2027.

Bluejay Diagnostics (BJDX) filed a resale registration covering up to 6,930,000 shares of common stock. The shares may be sold from time to time by the selling stockholders identified in the prospectus. The registered shares consist of 175,000 PIPE Shares, 2,075,000 shares issuable upon exercise of Pre-Funded Warrants, 4,500,000 shares issuable upon exercise of Series F Warrants, and 180,000 shares issuable upon exercise of Placement Agent Warrants, all issued in October 2025.

The company is not selling shares in this offering and will not receive proceeds from any resale by the selling stockholders. Bluejay will receive net proceeds only if warrants are exercised for cash. The common stock trades on Nasdaq as “BJDX”; the closing price was $2.56 per share on October 21, 2025. Certain warrants contain beneficial ownership limits of 4.99% or 9.99%, which cap exercises that would exceed those thresholds.

Bluejay Diagnostics entered into a private placement that closed on October 10, 2025, selling 175,000 shares of common stock and pre-funded warrants for up to 2,075,000 shares, together with Series F warrants for up to 4,500,000 shares. The combined price was $2.00 per share (or pre-funded warrant) plus accompanying Series F warrants to acquire two shares. The company received approximately $4.0 million in proceeds after fees.

Pre-funded warrants are immediately exercisable at $0.0001 per share and expire once exercised. Series F warrants are immediately exercisable at $1.75 per share and expire five and one-half years from issuance. The placement agent received warrants to purchase up to 180,000 shares, with an exercise price equal to 125% of the combined price per share and Series F warrants sold.

Bluejay agreed to register for resale the 175,000 shares and 6,755,000 warrant shares, file by October 24, 2025, and keep the registration effective until the registered shares may be sold under Rule 144. Issuances are restricted for 90 days after effectiveness, and certain variable-rate deals and splits are limited for one year. Warrant exercises are capped at 4.99% or 9.99% beneficial ownership, subject to notice-based adjustments.

Bluejay Diagnostics, Inc. furnished a Current Report stating that, following its quarterly report for the fiscal quarter ended June 30, 2025, the company issued a press release providing a 2025 second quarter business and corporate update.

The press release is furnished as Exhibit 99.1 and the cover page interactive data file is included as Exhibit 104. The filing specifies the information is being furnished and is not "filed" under the Exchange Act and will not be incorporated by reference into other filings unless identified. The report was signed by Neil Dey, President and Chief Executive Officer.